tiprankstipranks
Trending News
More News >

Sihuan Pharmaceutical’s New Breast Cancer Treatment Gains Regulatory Acceptance

Story Highlights
  • Sihuan Pharmaceutical’s NDA for Bireociclib’s new indication was accepted by NMPA.
  • The acceptance strengthens Sihuan’s R&D capabilities and market position in breast cancer treatment.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Sihuan Pharmaceutical’s New Breast Cancer Treatment Gains Regulatory Acceptance

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).

Sihuan Pharmaceutical Holdings Group announced that their New Drug Application for a new indication of Bireociclib Tablets, in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer, has been accepted by China’s National Medical Products Administration. This development highlights the company’s strong R&D capabilities and positions them to provide comprehensive treatment options for breast cancer patients, addressing a significant demand in the global market for CDK4/6 inhibitors, which is projected to grow substantially.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group, through its subsidiary Xuanzhu Biopharmaceutical, is an innovative pharmaceutical company based in China with a global outlook. The company focuses on major diseases such as oncology and digestion, and specializes in the research, development, production, and commercialization of class 1 drugs. Xuanzhu Biopharmaceutical employs a dual-platform approach with small molecule chemistry and large molecule biologics to drive innovation and development.

YTD Price Performance: 56.06%

Average Trading Volume: 75,703,865

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.61B

Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1